STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
Cell Immunol
; 366: 104384, 2021 08.
Article
en En
| MEDLINE
| ID: mdl-34182334
ABSTRACT
Despite impressive clinical success, cancer immunotherapy based on immune checkpoint blockade remains ineffective in colorectal cancer (CRC). Stimulator of interferon genes (STING) is a novel potential target and STING agonists have shown potential anti-tumor efficacy. Combined therapy based on synergistic mechanism can overcome the resistance. However, STING agonists-based combination therapies are deficient. We designed different immunotherapy combinations, including STING agonist, indoleamine 2,3 dioxygenase (IDO) inhibitor and PD-1 blockade, with purpose of exploring which option can effectively inhibit CRC growth. To further explore the possible reasons of therapeutic effectiveness, we observed the combination therapy in C57BL/6Tmem173gt mice. Our findings demonstrated that STING agonist diABZI combined with IDO inhibitor 1-MT significantly inhibited tumor growth, even better than the three-drug combination, promoted the recruitment of CD8+ T cells and dendritic cells, and decreased the infiltration of myeloid-derived suppressor cells. We conclude that diABZI combined with 1-MT is a promising option for CRC.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Triptófano
/
Bencimidazoles
/
Neoplasias Colorrectales
/
Adenocarcinoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Linfocitos T CD8-positivos
/
Indolamina-Pirrol 2,3,-Dioxigenasa
/
Células Supresoras de Origen Mieloide
/
Inmunoterapia
/
Proteínas de la Membrana
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Cell Immunol
Año:
2021
Tipo del documento:
Article